@inproceedings{inproceedings, title  = {{A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2<sup>-</sup> hormone receptor<sup>+</sup> breast cancer patients (pts) with bone metastases (mets).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1104 }},

 year = {{2015}},

 month = {{5}},

 author = {{Coleman RE and Huang L and Petrenciuc O and Zaccarini P}},

 doi = {{10.1200/jco.2015.33.15_suppl.tps1104}},

 volume = {{33}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{TPS1104-TPS1104}},

 note = {{Accessed on 2025/10/10}}}